OTC Markets EXMKT - Delayed Quote ? USD Vaxxinity, Inc. (VAXX) Follow Compare 0.0600 0.0000 (0.00%) As of 10:18 AM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC: VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy med GlobeNewswire ? 4 months ago VAXX 0.00% Vaxxinity Issues Shareholder Letter CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longe GlobeNewswire ? 5 months ago VAXX 0.00% Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Sectio GlobeNewswire ? 5 months ago VAXX 0.00% Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral Pr GlobeNewswire ? 6 months ago VAXX 0.00% Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company’s first approval,” said Mei Mei Hu, CEO o GlobeNewswire ? 6 months ago VAXX 0.00% Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD? 2024 UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson’s disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD? 2024 International Conference on A GlobeNewswire ? 7 months ago VAXX 0.00% Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting PCSK9, the company said in a statement. The studies were published in the Journal of […] Exec Edge ? 8 months ago VAXX 0.00% Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies dem GlobeNewswire ? 8 months ago VAXX 0.00% Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Por GlobeNewswire ? 8 months ago VAXX 0.00% Vaxxinity, UF Join Forces Against Neurodegenerative Diseases By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it’s with the University of Florida’s Center for Translational Research in Neurodegenerative Disease (CTRND) to develop vaccines for diseases like Alzheimer’s and Parkinson’s. The collaboration aims to understand and neutralize toxic brain proteins, Vaxxinity said. UF researchers will conduct preclinical studies to evaluate candidates and potentially offer […] Exec Edge ? 8 months ago VAXX 0.00% Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s ac GlobeNewswire ? 8 months ago VAXX 0.00% Vaxxinity & UCF to Collaborate on Space Medicine Research By Karen E. Roman Vaxxinity, Inc. (NASDAQ: VAXX) said it will collaborate with the University of Central Florida in the advancement of space medicine research through a grant funded by the state of Florida. The goal is to further develop the company’s active immunotherapies to prevent and mitigate muscle and bone wasting, frequent in long-term […] Exec Edge ? 8 months ago VAXX 0.00% Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to GlobeNewswire ? 8 months ago VAXX 0.00% Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST. About Vaxxinity Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare acr GlobeNewswire ? 9 months ago VAXX 0.00% The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. Zacks ? 10 months ago ACIU VAXX 0.00% PRTA FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. Reuters ? 10 months ago VAXX 0.00% PRTA ACIU Vaxxinity to Present at Upcoming November Medical and Investor Conferences CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi GlobeNewswire ? 11 months ago VAXX 0.00% Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have GlobeNewswire ? 11 months ago VAXX 0.00% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return VAXX S&P 500 YTD -92.94% +22.65% 1-Year -93.43% +38.50% 3-Year -99.64% +25.83%
